Medication failure leads 45% of respondents with depression and/or anxiety to turn to unhealthy coping mechanisms Respondents may view these behaviors...
CHATHAM, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced...
Creative Health Care Management (CHCM) Webinar May 12, 2023Bloomington, MN, April 17, 2023 (GLOBE NEWSWIRE) -- Zina Rodriguez, MSW, CDE...
SEATTLE and VANCOUVER, British Columbia, April 14, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...
Streamlining Phase 3 Fibromyalgia and Phase 2 Chronic Migraine Trials by Eliminating Interim Analyses Topline Results Expected for Both Programs...
— Presentation entitled "BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility" — — First-in-human Phase 1 trial for lead program,...
Survey finds the DEA’s proposed rules, which limit access to buprenorphine through telemedicine, will have outsized impact on low-income households...
CENTER CITY, Minn. and VANCOUVER, British Columbia, April 05, 2023 (GLOBE NEWSWIRE) -- The Hazelden Betty Ford Foundation and TELUS...
Data from Animal Studies on TNX-1700 (recombinant TFF2 – albumin fusion peptide) in Syngeneic Models of Colorectal and Gastric Cancer...
Revenue Increases 343% for 2022 Due to Increased Number of Patients Treated at Licensed Clinics ANAHEIM, CA, April 03, 2023...
DENVER, March 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"),...
SEATTLE, Wash. and VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage...
OLINVYK-treated patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of stay compared to matched...
VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or “The Company”) , an early-stage...
Topline Data Expected in 2Q 2023SEATTLE, Wash. and VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences,...
Real-World Evidence Demonstrates the Highest Response and Remission Rates Observed to Date for Deep BURLINGTON, Mass. and JERUSALEM, March 28, 2023...
atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living...
CHATHAM, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced...
The Keswick Group is led by experienced pharmaceutical business development executive, Tony GoodmanCHARLOTTESVILLE, Va., March 21, 2023 (GLOBE NEWSWIRE) --...
Patient feedback from the standardized Brief Addiction Monitor (BAM) assessment demonstrates reductions in drug and alcohol usage, and other risk...